Drug intelligence / Profile preview

chloramphenicol + imipenem + trimethoprim-sulfamethoxazole

Development stage: Preclinical
Lead developer: Pfizer
Modality: Small Molecules
Administration: Intravenous, Oral, Intramuscular

Overview

This is a combination of three antimicrobial agents: chloramphenicol (a protein synthesis inhibitor), imipenem (a carbapenem antibiotic), and trimethoprim-sulfamethoxazole (a folate synthesis inhibitor combination). This combination may be used for severe infections, particularly melioidosis, where multiple antimicrobial agents with different mechanisms of action are needed to effectively treat the infection.

Targets

PBP (Penicillin-binding protein family)DHFR (Dihydrofolate reductase)DHPS (Dihydropteroate synthase)Bacterial 50S ribosomal subunit

Beyond the preview

Go deeper on chloramphenicol + imipenem + trimethoprim-sulfamethoxazole.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on chloramphenicol + imipenem + trimethoprim-sulfamethoxazole.

Explore the full profile